This highlights the significance of the HIF-1/EZH2 signaling in the poor prognosis of ERα-negative breast cancer patients and the potential for drug combination to intervene in the ERα-FOXK2-HIF1β/EZH2 axis. This evidence concerns the gene EZH2 and breast cancer.